Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.

Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.

Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.

Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.

Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.

Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.

Indication: It is suitable for the induction remission and continued treatment stages of various types of acute non-lymphocytic leukemia, especially for acute promyelocytic leukemia, acute monocytic leukemia, and acute myeloid leukemia. It also has certain effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia, and polycythemia vera.

Indication: It is suitable for the induction remission and continued treatment stages of various types of acute non-lymphocytic leukemia, especially for acute promyelocytic leukemia, acute monocytic leukemia, and acute myeloid leukemia. It also has certain effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia, and polycythemia vera.

Indication: Jakafi is a kinase inhibitor indicated for treatment of: intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults. 1 polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. 2 steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older ( 1. 3 chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. 4 Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults. Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older. Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.